Navigation Links
New Scan May Help Find Aggressive Prostate Tumors
Date:1/27/2010

Process is among several that use a variation of MRI technology

WEDNESDAY, Jan. 27 (HealthDay News) -- A new imaging technology promises to achieve the long-sought goal of singling out prostate cancers that are life-threatening and require the most aggressive treatment, researchers report.

Magnetic resonance spectroscopy, which provides information about the metabolic chemistry of suspected cancerous tissue, gave good results in a small trial in which its readings were compared with those of current measures of prostate cancer danger, according to a report published Jan. 27 in Science Translational Medicine.

"We see a good correlation with pathology defined by those methods," said Leo L. Cheng, an assistant professor of radiology and pathology at Harvard Medical School and a researcher at Massachusetts General Hospital.

Prostate cancers are common among older men, but most of them are so slow-growing that they pose no danger to life. Current diagnostic techniques, which include readings of blood levels of a protein, prostate-specific antigen, cannot pick out the dangerous tumors. Doctors can take a tissue sample by doing a biopsy, but they often miss the small but deadly portion of the cancer that is growing aggressively enough to be life-threatening.

In 2005, Cheng and his colleagues found that magnetic resonance spectroscopy could distinguish cancerous from normal prostate tissue by their metabolic profiles. That's because cancerous tissue produces different chemicals than normal tissue.

Their new study used magnetic resonance spectroscopy on five cancerous prostate glands removed from men with the diagnosis. The results of the scans were compared with those of the standard technique, which judges a cancer by the degree of disorder produced by the malignancy. Five of seven regions identified as cancerous by that method scored high on a magnetic resonance spectroscopy malignancy index. The other two regions were near the outer edges of the glands, where exposure to air made the magnetic resonance results less clear.

The same kind of analysis can be done without removing the prostate glands, so Cheng and his colleagues are moving toward a trial that would more resemble the work now done by doctors.

"We are doing a validation study," Cheng said. "Once these data are verified, we need to work with the electronics people to develop more sensitive probes. Once that part is overcome, everything can be applied."

The validation study will take "optimistically, one to three months," Cheng said. Getting data showing that the technology can be used in human patients "will take some time, a year or two," he said.

When and if it comes to human trials, "the most urgent issue is to guide biopsies," Cheng said. "By taking a chemical spectrum of tissue, we may be able to do better than pathology to tell how aggressive a tumor is."

The technology currently requires a magnetic field far more powerful than those in magnetic resonance imaging devices in current medical use, and so part of the program at Massachusetts General Hospital is an effort to make the method usable in less powerful devices, he said.

Cheng's program is one of a number of efforts aimed at applying magnetic resonance imaging to prostate cancer diagnosis. Another already is available commercially, marketed by iCAD Inc., a New Hampshire-based company.

The iCAD technology uses "dynamic contrast-enhanced" imaging, said Marc Filerman, vice president of global marketing for the company. Gadolinium, a contrast agent, is injected into the prostate gland "to produce images that better highlight where the potentially cancerous lesion might be," he said.

Gadolinium concentrates in regions where there are fast-growing blood vessels that the voracious expansion of cancerous tissue requires, he said. "Those blood vessels are leaky, and the resulting images enable us to quantify a potentially cancerous lesion, to see the effect of treatment," Filerman said.

Work to improve existing technologies is continuing, he said. "What we are trying to do in the magnetic resonance imaging community is to standardize on the best methodology for image acquisition and interpretation," Filerman explained.

More information

The U.S. National Cancer Institute has more on prostate cancer.



SOURCES: Leo L. Cheng, Ph.D., assistant professor, radiology and pathology, Harvard Medical School, and researcher, Massachusetts General Hospital, Boston; Marc Filerman, vice president, global marketing, iCAD Inc., Nashua, N.H.; Jan. 27, 2010, Science Translational Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Genetic Marker for Aggressive Prostate Cancer Found
2. More Aggressive Treatment for Weekend Stroke
3. Genetic variant associated with aggressive form of prostate cancer
4. Protein link may be key to new treatment for aggressive brain tumor
5. Aggressive Infection Control Program Protects Cancer Patients from Acquiring Clinic-Based H1N1 Influenza
6. AdCare Health Systems Completes Private Placement to Fund Aggressive Growth Initiatives
7. Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkins Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
8. Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines
9. MS is more aggressive in children but slower to cause disability than in adults
10. Elderly Treated Less Aggressively for Heart Attack
11. Nations hip fracture rate could drop 25 percent with aggressive osteoporosis prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., the maker ... data center assets and audio-video devices has recently updated its Visio Stencils library ... free and download shapes and stencils from http://www.VisioStencils.com. , New devices ...
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
(Date:3/29/2017)... Ca (PRWEB) , ... March 29, 2017 , ... ... process in many scientific laboratories. The assembly protocols involve many repetitive steps and ... suited for automation, which enables the high-throughput needed, and results in a lower ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 ... report, which provides an exhaustive study of the U.S. ... nearly 242 companies are functional in this market ... With the leading companies, such as GlaxoSmithKline Plc., ... focusing aggressively on various marketing strategies to increase ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global lifestyle drugs market to grow ... The report, Global Lifestyle Drugs Market 2017-2021, has been prepared ... The report covers the market landscape and its growth prospects over ...
(Date:3/29/2017)... , March 29, 2017 Varian Medical Systems ... report results for the second quarter of fiscal year 2017 ... 2017.  The news release will be followed by a teleconference ... news release and a link to the conference call webcast ... .  To access the teleconference call and replay: ...
Breaking Medicine Technology: